News Features
- Elan Names John Moriarty Jr. as General Counsel
- Elan Announces New Appointments in BioNeurology and EDT Businesses
- "Novel Approaches" Program Awards Six Parkinson’s Research Teams
- Developing New Diagnostic Approaches for Alzheimer’s Disease
- Dale Schenk, Chief Scientific Officer, Discusses the Recent Collaboration with PharmatrophiX
- Fampridine-SR Licensed in Markets Outside the United States
- Elan and PharmatrophiX Announce Collaborative Pact
- Elan Announces the Formation of Exploratory Research Group
- Menghis Bairu Joins OneWorld Health Board of Directors
- AN1792 Long-Term Follow-Up Published and Available Online
- Elan Participates in Alzheimer's Association Public Policy Forum
- Elan at AD/PD: Continued Scientific Leadership
- Elan President Carlos Paya On TYSABRI News Reports
- Dale Schenk, Chief Scientific Officer, Discusses Alzheimer’s Disease Research Assertions